Agios Pharmaceuticals Exercises Option To U.S. Development And Commercialization Rights For IDH1 Program Under Celgene Collaboration
Published: Feb 03, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, announced today that it has elected to retain the United States development and commercial rights to the isocitrate dehydrogenase 1 (IDH1) program including the clinical candidate AG-120, in accordance with the terms of its global strategic collaboration with Celgene Corporation in the field of cancer metabolism.
Help employers find you! Check out all the jobs and post your resume.